移植后淋巴增殖性疾病研究进展  

Progress on post transplant lymphoproliferative disorder

作　　者：陈奥 练巧燕 张建恒[1] 徐鑫[1] 韦兵[1] 蔡宇航 王春燕[1] 谭获[1] 何建行[1] 巨春蓉[1] Chen Ao;Lian Qiaoyan;Zhang Jianheng;Xu Xin;Wei Bing;Cai Yuhang;Wang Chunyan;Tan Huo;He Jianxing;Ju Chunrong(Department of Transplantation,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou Institute of Respiratory Health,Guangzhou 510012,China)

机构地区：[1]广州医科大学附属第一医院移植科广州呼吸健康研究院,510012

出　　处：《中华移植杂志（电子版）》2021年第5期307-312,共6页Chinese Journal of Transplantation(Electronic Edition)

基　　金：呼吸疾病国家重点实验室青年自主课题(SKLRD-QN-201710);2019年度广州呼吸健康研究院/广医一院临床研究中心临床自主探索项目(2019GIRHZ04)。

摘　　要：移植后淋巴增殖性疾病(PTLD)是实体器官移植(SOT)术后最严重的并发症之一。PTLD严重影响移植受者生存时间,其发病与EB病毒(EBV)感染和机体免疫功能受抑制等相关,组织病理学是其诊断金标准。目前治疗方案包括免疫抑制剂减量、利妥昔单抗、EBV特异性细胞毒性T细胞输注及化疗等,但SOT术后并发PTLD受者总体预后仍较差。本文主要对近年来SOT术后并发PTLD研究进展作一综述,以期为临床更好地诊断SOT术后PTLD发生及早期干预提供理论及实践指导。Post-transplant lymphoproliferative disorder(PTLD)is one of the most serious complications after solid organ transplantation(SOT).PTLD seriously affects the survival time of transplant recipients,the incidence of PTLD is related to Epstein-Barr virus(EBV)infection and suppression of immune function,and histopathology is the gold standard for its diagnosis.Current treatment options include dose-reduction of immunosuppressant,rituximab,EBV specific cytotoxic T lymphocyte infusion and chemotherapy,and so on,but the overall prognosis of PTLD patients is still poor.This review mainly summarizes the research progress of PTLD after SOT in recent years,in order to diagnose the occurrence of PTLD after SOT better,and provide theoretical and practical guidance for early intervention.

关 键 词：移植后淋巴增殖性疾病 实体器官移植 EB病毒 

分 类 号：R551.2[医药卫生—血液循环系统疾病] R617[医药卫生—内科学]